Table 2.
Best overall response in Japanese patients with relapsed or refractory multiple myeloma randomized to bortezomib + dexamethasone (BD) or thalidomide + dexamethasone (TD) treatment arms (n = 44)
| Best response | BD (n = 22) | TD (n = 22) |
|---|---|---|
| Overall response ratea | 77.3 (95% CI, 54.6‐92.2) | 40.9 (95% CI, 20.7‐63.7) |
| P = .0305 | ||
| Best response | ||
| Stringent complete response | 1 (4.5) | 0 (0.0) |
| Complete response | 1 (4.5) | 0 (0.0) |
| Very good partial response | 2 (9.1) | 3 (13.6) |
| Partial response | 13 (59.1) | 6 (27.3) |
| Stable disease | 4 (18.2) | 7 (31.8) |
| Progressive disease | 0 (0.0) | 5 (22.7) |
| Not evaluable | 1 (4.5) | 1 (4.5) |
CI, confidence interval.
a
Partial response or better.